Avicanna is a brand-new company record, and its full research profile isn't ready yet.
avicanna.comCrawled Oct 26, 2026
Pharmaceutical Pipeline of Indication Specific Products Developed Through the Company’s R&D, Clinical and Commercial Platforms Pharmaceutical Pipeline Indication-Specific Products Trunerox 10% CBD Oral Solution Adjunctive Treatment Of Seizures Associated with Lennox Gastaut Syndrome (LGS) and Dravet Syndrome (DS) Trunerox is a pharmaceutical drug with proprietary formulation manufactured under GMP standards and utilizing the Company’s purified […]
Avicanna’s Aureus platform provides pharmaceutical-grade cannabinoid APIs, supporting global manufacturing and clinical operations.
Avicanna announced its QUIX-powered rapid-onset medical cannabis portfolio, with initial products launching in Canadian medical channels in late 2026.
Cannabis, or marijuana, is primarily smoked as a euforic plant, though its effects vary by user.
Vertical Companies and other cannabis businesses presented their operations and industry outlook at the Benzinga Cannabis Capital Conference in Toronto.
The page debates whether cannabis farming’s rapid growth in the United States contributes to climate change through industrial agriculture practices.
The European Parliament passed a resolution supporting medical marijuana, aligning with the World Health Organization’s recommendation for cannabis rescheduling.
Avicanna completed its first commercial export of feminized cannabis seeds to Pe via its Colombian subsidiary, Santa Marta Golden Hemp S.A.S.
Avicanna registered and exported its Pura Earth dermacosmetics products to Ecuador.
Aras Azadian, CEO of Avicanna, founded the company to develop cannabinoid-based pharmaceuticals, leveraging biotechnology and management consulting expertise.
Avicanna is a biopharmaceutical company advancing evidence-based cannabinoid products for medical and pharmaceutical markets, with over nine years of R&D.
Avicanna aims to lead the global medical cannabis industry through research, cultivation, intellectual property, and strategic partnerships.
Avicanna develops cannabinoid-based pharmaceuticals using scientific and evidence-based approaches.